

Dopamine ELISA Kit

Catalog Number KA1887

96 assays

Version: 15

Intended for research use only



Table of Contents

| Int | oduction | 3 |
|-----|-------------------------------------|------|
| | Intended Use | 3 |
| | Background | 3 |
| | Principle of the Assay | 3 |
| Ge | neral Information | 4 |
| | Materials Supplied | 4 |
| | Storage Instruction | 5 |
| | Materials Required but Not Supplied | 5 |
| | Precautions for Use | 6 |
| As | say Protocol | 8 |
| | Reagent Preparation | 8 |
| | Sample Preparation | 8 |
| | Assay Procedure | 8 |
| Da | ta Analysista | 11 |
| | Calculation of Results | . 11 |
| | Performance Characteristics | . 12 |
| Re | sources | 14 |
| | References | . 14 |
| | Plate Layout | . 15 |



Introduction

Intended Use

Enzyme Immunoassay for the quantitative determination of dopamine in plasma and urine.

Background

In humans the catecholamines adrenaline (epinephrine), noradrenaline (norepinephrine) and dopamine are neurotransmitters of the sympathetic nervous system and are involved in many physiological processes. The sympathetic nervous system sets the body to a heightened state of alert, also called as the body's fight-or-flight response.

In the human body the catecholamines and their metabolites indicate the adaption of the body to acute and chronic stress.

Principle of the Assay

Dopamine is extracted by using a cis-diol-specific affinity gel, acylated and then converted enzymatically.

The competitive ELISA kit uses the microtiter plate format. The antigen is bound to the solid phase of the microtiter plate. The derivatized standards, controls and samples and the solid phase bound analytes compete for a fixed number of antibody binding sites. After the system is in equilibrium, free antigen and free antigen-antibody complexes are removed by washing. The antibody bound to the solid phase is detected by an anti-rabbit IgG-peroxidase conjugate using TMB as a substrate. The reaction is monitored at 450 nm.

Quantification of unknown samples is achieved by comparing their absorbance with a standard curve prepared with known standard concentrations.



General Information

Materials Supplied

List of component

| Component | Amount | |
|---|-----------------|--|
| Adhesive Foil: Ready to use, in a resealable pouch. | 4 slices | |
| Wash Buffer Concentrate (50x): Concentrated buffer with a non-ionic detergent and | 20 | |
| physiological pH, light purple cap. | 20 mL | |
| Enzyme Conjugate: Ready to use, goat anti-rabbit immunoglobulins, conjugated with | 12 mL | |
| peroxidase, red cap. | 12 IIIL | |
| Substrate: Ready to use, chromogenic substrate containing tetramethylbenzidine, substrate | 12 mL | |
| buffer and hydrogen peroxide, black cap. | 12 IIIL | |
| Stop Solution: Ready to use, containing 0.25 M sulfuric acid, light grey cap. | | |
| Hazards identification: H290 May be corrosive to metals. | 12 mL | |
| Dopamine Antiserum: Ready to use, rabbit anti-dopamine antibody, green coloured, dark | | |
| green cap. | 6 mL | |
| Adjustment Buffer: Ready to use, TRIS buffer, green cap. | 4 mL | |
| Acylation Buffer: Ready to use, buffer with light alkaline pH for the acylation, white cap. | 20 mL | |
| Acylation Reagent: Ready to use. Acylation reagent in DMF and DMSO, light red cap. | 20 IIIL | |
| Hazards identification: H360D May damage the unborn child. H226 Flammable liquid and vapour. | 3 mL | |
| H312 + H332 Harmful in contact with skin or if inhaled. | | |
| H319 Causes serious eye irritation. | | |
| Assay Buffer: Ready to use, 1 M hydrochloric acid and a non-mercury preservative, light grey cap. | 6 mL | |
| Coenzyme: Ready to use, S-adenosyl-L-methionine, purple cap. | 4 mL | |
| Enzyme: Lyophilized Catechol-O-methyltransferase, pink cap. | 2 vials | |
| Extraction Buffer: Ready to use, buffer containing carbonate, brown cap. | 6 mL | |
| Extraction Plate: Ready to use, plates coated with boronate affinity gel in a resealable pouch. | 48 wells x 2 | |
| Hydrochloric Acid: Ready to use, 0.025 M hydrochloric acid, yellow coloured, dark green cap. | 20 mL | |
| Dopamine Microtiter Strips: Ready to use, antigen precoated microwell plate in a resealable green pouch with desiccant. | 96 (8x12) wells | |



Standards and Controls - Ready to use

| Component | Color/Cap | Concentration (ng/mL) | Concentration (nmol/L) | Amount |
|------------------|--------------|--|------------------------|--------|
| Standard A white | | 0 | 0 | 4 mL |
| Standard B | light yellow | 10 | 65 | 4 mL |
| Standard C | orange | 40 | 261 | 4 mL |
| Standard D | dark blue | 150 | 980 | 4 mL |
| Standard E | light grey | 500 | 3265 | 4 mL |
| Standard F | black | 2000 | 13060 | 4 mL |
| Standard A/B | light purple | 4.5 | 29 | 4 mL |
| Control 1 | light green | Refer to QC report for expected value and acceptable | | 4 mL |
| Control 2 | dark red | range. | | 4 mL |

Conversion: Dopamine (ng/mL) x 6.53 = Dopamine (nmol/L)

Content: Acidic buffer with non-mercury stabilizer, spiked with defined quantity of dopamine

Storage Instruction

Store the unopened reagents at 2-8°C until expiration date. Do not use components beyond the expiry date indicated on the kit labels. Once opened the reagents are stable for 1 month when stored at 2-8°C. Once the resealable pouch has been opened, care should be taken to close it tightly with desiccant again.

Materials Required but Not Supplied

- ✓ Calibrated precision pipettes to dispense volumes between 10-700 µL; 1 mL.
- ✓ Microtiter plate washing device (manual, semi-automated or automated).
- ✓ ELISA reader capable of reading absorbance at 450 nm and if possible 620 650 nm.
- ✓ Microtiter plate shaker (shaking amplitude 3 mm; approx. 600 rpm).
- ✓ Absorbent material (paper towel).
- ✓ Water (deionized, distilled, or ultra-pure).
- ✓ Vortex mixer

^{*}for the determination of dopamine in plasma the additional Standard A/B is mandatory!



Precautions for Use

- Procedural cautions, guidelines and warnings
- This kit is intended for professional use only. Users should have a thorough understanding of this protocol for the successful use of this kit. Only the test instruction provided with the kit is valid and has to be used to run the assay. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
- ✓ The principles of Good Laboratory Practice (GLP) have to be followed.
- ✓ In order to reduce exposure to potentially harmful substances, wear lab coats, disposable protective gloves and protective glasses where necessary.
- ✓ All kit reagents and specimens should be brought to room temperature and mixed gently but thoroughly before use. Avoid repeated freezing and thawing of reagents and specimens.
- ✓ For dilution or reconstitution purposes, use deionized, distilled, or ultra-pure water.
- ✓ The microplate contains snap-off strips. Unused wells must be stored at 2 °C to 8 °C in the sealed foil pouch with desiccant and used in the frame provided.
- ✓ Duplicate determination of sample is highly recommended to be able to identify potential pipetting errors.
- ✓ Once the test has been started, all steps should be completed without interruption. Make sure that the required reagents, materials and devices are prepared ready at the appropriate time.
- ✓ Incubation times do influence the results. All wells should be handled in the same order and time intervals.
- ✓ To avoid cross-contamination of reagents, use new disposable pipette tips for dispensing each reagent, sample, standard and control.
- ✓ A standard curve must be established for each run.
- ✓ The controls should be included in each run and fall within established confidence limits. The confidential limits are listed in the QC-Report provided with the kit.
- ✓ Do not mix kit components with different lot numbers within a test and do not use reagents beyond expiry date as shown on the kit labels.
- ✓ Avoid contact with Stop Solution containing 0.25 M H₂SO₄. It may cause skin irritation and burns. In case of contact with eyes or skin, rinse off immediately with water.
- ✓ TMB substrate has an irritant effect on skin and mucosa. In case of possible contact, wash eyes with an abundant volume of water and skin with soap and abundant water. Wash contaminated objects before reusing them.
- ✓ For information on hazardous substances included in the kit please refer to Material Safety Data Sheet (MSDS). The Material Safety Data Sheet for this product is made available directly on the website of the manufacturer or upon request.
- Kit reagents must be regarded as hazardous waste and disposed according to national regulations.



Limitations

Any inappropriate handling of samples or modification of this test might influence the results.

• Interfering substance

✓ Plasma

Samples containing precipitates or fibrin strands or which are haemolytic or lipemic might cause inaccurate results.

√ 24-hour urine

Please note the sample preparation! If the percentage of the final concentration of acid is too high, this will lead to incorrect results for the urine samples.

• Drug interferences

There are no known substances (drugs) which ingestion interferes with the measurement of dopamine level in the sample.

High-Dose-Hook effect

No hook effect was observed in this test.



Assay Protocol

Reagent Preparation

✓ Wash Buffer

Dilute the 20 mL Wash Buffer Concentrate with water (deionized, distilled, or ultra-pure) to a final volume of 1000 mL.

Storage: 1 month at 2-8°C.

✓ Enzyme Solution

Reconstitute the content of the vial labelled 'Enzyme' with 1 mL water (deionized, distilled, or ultra-pure) and mix thoroughly. Add 0.3 mL of Coenzyme followed by 0.7 mL of Adjustment Buffer. The total volume of the Enzyme Solution is 2.0 mL.

Note: The Enzyme Solution has to be prepared freshly prior to the assay (not longer than 10-15 minutes in advance). Discard after use!

✓ Dopamine Microtiter Strips

In rare cases residues of blocking and stabilizing reagent can be seen in the wells as small, white dots or lines. These residues do not influence the quality of the product.

Sample Preparation

✓ Plasma

Whole blood should be collected into centrifuge tubes containing EDTA as anti-coagulant (Monovette™ or Vacuette™ for plasma) and centrifuged according to manufacturer's instructions immediately after collection. Haemolytic and lipemic samples should not be used for the assay.

Storage: up to 6 hours at 2-8°C; for longer periods (up to 6 months) at -20°C.

Repeated freezing and thawing should be avoided.

✓ Urine

Spontaneous or 24-hours urine, collected in a bottle containing 10-15 mL of 6 M HCl, can be used. If 24-hour urine is used please record the total volume of the collected urine.

Storage: Up to 48 hours at 2-8°C, up to 24 hours at room temperature, for longer periods (up to 6 months) at -20°C. Repeated freezing and thawing should be avoided. Avoid exposure to direct sunlight.

Assay Procedure

- ✓ Allow all reagents to reach room temperature and mix thoroughly by gentle inversion before use.
- ✓ Duplicate determinations are recommended.
- ✓ It is recommended to number the strips of the microwell plate before usage to avoid any mix-up.
- ✓ The binding of the antiserum and the enzyme conjugate and the activity of the enzyme used are temperature dependent, and the absorbance may vary if a thermostat in not used. The higher the



temperature, the higher the absorbance will be. Varying incubation times will have a similar influence on the absorbance. The optimal temperature during the Enzyme Immunoassay is between 20-25°C.

Note: In case of overflow, read the absorbance of the solution in the wells within 10 minutes, using a microplate reader set to 405 nm.

- ✓ Sample preparation, extraction and acylation

 Note: for the determination of dopamine in plasma the additional Standard A/B is mandatory!
- 1. Pipette 10 μ L of standards, controls, urine samples and 300 μ L of plasma samples into the respective wells of the Extraction Plate.
- 2. Add 250 μ L of water (deionized, distilled, or ultra-pure) to the wells with standards, controls and urine samples.
- 3. Pipette 50 µL of Assay Buffer into all wells
- 4. Pipette 50 µL of Extraction Buffer into all wells
- 5. Cover plate with Adhesive Foil and incubate 30 min at RT (20-25°C) on a shaker (approx. 600 rpm).
- 6. Remove the foil. Empty plate and blot dry by tapping the inverted plate on absorbent material.
- 7. Pipette 1 mL of Wash Buffer into all wells. Incubate the plate for 5 min at RT (20-25°C) on a shaker (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- 8. Pipette another 1 mL of Wash Buffer into all wells. Incubate the plate for 5 min at RT (20-25°C) on a shaker (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- 9. Pipette 150 µL of Acylation Buffer into all wells.
- 10. Pipette 25 µL of Acylation Reagent into all wells.
- 11. Incubate 15 min at RT (20-25°C) on a shaker (approx. 600 rpm).
- 12. Empty plate and blot dry by tapping the inverted plate on absorbent material.
- 13. Pipette 1 mL of Wash Buffer into all wells. Incubate the plate for 10 min at RT (20-25°C) on a shaker (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- 14. Pipette 175 μ L of Hydrochloric Acid into all wells.
- 15. Cover plate with adhesive foil. Incubate 10 min at RT (20-25°C) on a shaker (approx. 600 rpm). Remove the foil and discard.

Note: Do not decant the supernatant thereafter!

The following volumes of the supernatant are needed for the subsequent ELISA:

Dopamine (standards + urine):25 μL, Dopamine (plasma): 50 μL

- ✓ Dopamine ELISA
- 1. Pipette 25 μ L of the Enzyme Solution (refer to Reagent Preparation) into all wells of the Dopamine Microtiter Strips.
- 2. Pipette 25 μ L of the extracted standards, controls, urine samples and 50 μ L of the extracted plasma samples into the appropriate wells.
- 3. Add 25 µL of Hydrochloric Acid to the standards, controls and urine samples.
- 4. Incubate for 30 min at RT (20-25°C) on a shaker (approx. 600 rpm).
- 5. Pipette 50 µL of the Dopamine Antiserum into all wells and cover plate with Adhesive Foil.



- 6. Incubate for 2 hours at RT (20-25°C) on a shaker (approx. 600 rpm).
- 7. Remove the foil. Discard or aspirate the content of the wells. Wash the plate 3x by adding 300 μL of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- 8. Pipette 100 µL of the Enzyme Conjugate into all wells.
- 9. Incubate for 30 min at RT (20-25°C) on a shaker (approx. 600 rpm).
- 10. Discard or aspirate the content of the wells. Wash the plate 3x by adding 300 μL of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- 11. Pipette 100 μL of the Substrate into all wells and incubate for 25 ± 5 min at RT (20-25°C) on a shaker (approx. 600 rpm). *Note: Avoid exposure to direct sun light!*
- 12. Add 100 μ L of the Stop Solution to each well and shake the microtiter plate to ensure a homogeneous distribution of the solution.
- 13. Read the absorbance of the solution in the wells within 10 minutes, using a microplate reader set to 450 nm (if available a reference wavelength between 620 nm and 650 nm is recommended).



Data Analysis

Calculation of Results

✓ The standard curve is obtained by plotting the absorbance readings (calculate the mean absorbance) of the standards (linear, y-axis) against the corresponding standard concentrations (logarithmic, x-axis). Use a non-linear regression for curve fitting (e.g. spline, 4-parameter, akima).

Note: This assay is a competitive assay. This means: the OD-values are decreasing with increasing concentrations of the analyte. OD-values found below the standard curve correspond to high concentrations of the analyte in the sample and have to be reported as being positive.

| | | Dopamine |
|-----------------|--------|------------------|
| Measuring range | Urine | 4.8 – 2000 ng/mL |
| | Plasma | 75 – 33333 pg/mL |

✓ Urine samples and controls:

The concentrations of the urine samples and the Controls 1 & 2 can be read directly from the standard curve. Calculate the 24 h excretion for each urine sample: $\mu g/24 h = \mu g/L \times L/24 h$

✓ Plasma samples:

The read concentrations of the plasma samples have to be divided by 60.

✓ Conversion:

Dopamine $(ng/mL) \times 6.53 = Dopamine (nmol/L)$

✓ Expected Reference Values

It is strongly recommended that each laboratory should determine its own normal and abnormal values.


| | Dopamine | | | |
|---------------|------------------------------|--|--|--|
| 24-hour urine | < 600 µg/day (3900 nmol/day) | | | |
| Plasma | < 100 pg/mL | | | |

✓ Quality Control

The confidence limits of the kit controls are printed on the QC-Report.

✓ Typical Standard Curve

Example, do not use for calculation.





Performance Characteristics

✓ Analytical Sensitivity

| | | Dopamine |
|-----|----------------|----------|
| 100 | Urine (ng/mL) | 2.5 |
| LOD | Plasma (pg/mL) | 49 |
| 100 | Urine (ng/mL) | 4.8 |
| LOQ | Plasma (pg/mL) | 75 |

✓ Analytical Specificity (Cross Reactivity)

| Substance | Cross Reactivity (%) |
|--|----------------------|
| Substance | Dopamine |
| Derivatized Adrenaline | 0.02 |
| Derivatized Noradrenaline | 6.4 |
| Derivatized Dopamine | 100 |
| Metanephrine | < 0.01 |
| Normetanephrine | 0.01 |
| 3-Methoxytyramine | 0.49 |
| 3-Methoxy-4-hydroxyphenylglycol | < 0.01 |
| Tyramine | 0.18 |
| Phenylalanine, Caffeinic acid, L-Dopa, Homovanillic acid, Tyrosine, 3-Methoxy-4-hydroxymandelic acid | < 0.01 |

✓ Precision

| Intra-Assay Urine (n=60) | | | | Intra-Assay Plasma (n=60) | | | |
|--------------------------|-----------------------------|---------------|--------|---------------------------|---------------|---------------|--------|
| | Sample Range (ng/mL) CV (%) | | | Sample | Range (pg/mL) | CV (%) | |
| | 1 | 82 ± 16.1 | 19.7 | | 1 | 75 ± 22 | 29.8 |
| Dopamine | 2 | 253 ± 41.1 | 16.3 | Dopamine | 2 | 353 ± 86 | 24.4 |
| | 3 | 714 ± 67 | 9.4 | | 3 | 1187 ± 293 | 24.9 |
| Inter-Assay l | Jrine (n=33 |) | | Inter-Assay Plasma (n=18) | | | |
| | Sample | Range (ng/mL) | CV (%) | | Sample | Range (pg/mL) | CV (%) |
| | 1 | 79.3 ±18.8 | 23.7 | | 1 | 238 ± 67.0 | 28.2 |
| Dopamine | 2 | 222 ± 27.0 | 12.1 | Dopamine | 2 | 1072 ± 201 | 18.8 |
| | 3 | 630 ± 69.0 | 11.0 | | 3 | 3449 ± 491 | 14.2 |



✓ Linearity

| | | Serial dilution up to | Range (%) | Mean (%) |
|----------|--------|-----------------------|-----------|----------|
| Dopamine | Urine | 1:512 | 83 – 126 | 104 |
| | Plasma | 1:512 | 85 – 132 | 106 |

✓ Recovery

| | | Mean (%) | Range (%) | Range |
|----------|--------|----------|-----------|--------------------|
| Dopamine | Urine | 110 | 101-124 | 225 – 1306 ng/mL |
| | Plasma | 89 | 84-92 | 57.4 – 16054 pg/mL |



Resources

References

- Kim et al. Vitamin C prevents stress-induced damage on the heart caused by the death of cardiomyocytes, through the down-regulation of the excessive production of catecholamine, TNF-α, and ROS production in GULO(-I-) Vit C-Insufficient mice. Free Radical Biology and Medicine, 65:573-583 (2013).
- 2. Bada et al. Peripheral vasodilatation determines cardiac output in exercising humans: insight from atrial pacing. The Journal of Physiology, 590(8):2051-2060 (2012).
- 3. Parks et al. Employment and work schedule are related to telomere length in women. Occupational & Environmental Medicine 68(8):582-589 (2011).



Plate Layout

| | T | | | | | | | |
|--------|---|---|---|---|---|---|---|---|
| 12 | | | | | | | | |
| 11 | | | | | | | | |
| 10 | | | | | | | | |
| 6 | | | | | | | | |
| ω ω | | | | | | | | |
| | | | | | | | | |
| 2 | | | | | | | | |
| 9 | | | | | | | | |
| 5 | | | | | | | | |
| 4 | | | | | | | | |
| 8 | | | | | | | | |
| 2 | | | | | | | | |
| _ | | | | | | | | |
| | ∢ | B | O | ۵ | ш | Ш | O | I |